Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

464 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer.
Feng E, Rydzewski NR, Zhang M, Lundberg A, Bootsma M, Helzer KT, Lang JM, Aggarwal R, Small EJ, Quigley DA, Sjöström M, Zhao SG. Feng E, et al. Among authors: small ej. Clin Cancer Res. 2022 Dec 15;28(24):5396-5404. doi: 10.1158/1078-0432.CCR-22-2567. Clin Cancer Res. 2022. PMID: 36260524 Free PMC article.
Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study.
Ross RW, Halabi S, Ou SS, Rajeshkumar BR, Woda BA, Vogelzang NJ, Small EJ, Taplin ME, Kantoff PW; Cancer and Leukemia Group B. Ross RW, et al. Among authors: small ej. Clin Cancer Res. 2005 Nov 15;11(22):8109-13. doi: 10.1158/1078-0432.CCR-05-1250. Clin Cancer Res. 2005. PMID: 16299243
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Pagliaro LC, Harzstark AL, Sharib J, Small EJ. Rosenberg JE, et al. Among authors: small ej. J Clin Oncol. 2009 Jun 10;27(17):2772-8. doi: 10.1200/JCO.2008.19.8002. Epub 2009 Apr 6. J Clin Oncol. 2009. PMID: 19349545 Free PMC article.
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.
Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Ryan CJ, et al. Among authors: small ej. Clin Cancer Res. 2011 Jul 15;17(14):4854-61. doi: 10.1158/1078-0432.CCR-11-0815. Epub 2011 Jun 1. Clin Cancer Res. 2011. PMID: 21632851 Free PMC article. Clinical Trial.
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ; Alliance for Clinical Trials in Oncology. Aggarwal R, et al. Among authors: small ej. Cancer. 2013 Oct 15;119(20):3636-43. doi: 10.1002/cncr.28285. Epub 2013 Jul 31. Cancer. 2013. PMID: 23913744 Free PMC article. Clinical Trial.
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ. Harzstark AL, et al. Among authors: small ej. Cancer. 2011 Jun 1;117(11):2419-25. doi: 10.1002/cncr.25810. Epub 2010 Dec 29. Cancer. 2011. PMID: 24048789 Free article. Clinical Trial.
464 results